05 May 2023
|Index / Fund / Rate||Start of Year||Last week||This Week||% change YTD|
|Lunar BCI WW Flexible Fund||141.43||161.59||160.55||13.52%|
|JSE ALSI||73 049||78 218||78 133||6.96%|
|NASDAQ Composite||10 467||12 227||12 235||16.90%|
|S&P 500||3 840||4 169||4 136||7.71%|
|Prime Lending Rate||10,50%||11.25%||11.25%||7.14%|
|Brent Crude ($’barrel)||85,95||80.25||75.27||-12.43%|
Weekly Stocktake with Danyaal
Long Life Novo Nordisk
Over the last few decades, the average life expectancy in developed nations has been increasing. This has been due to a number of factors such as advancements in medical technology, improved public health measures, and a greater focus on preventative care. However, some consequences of people aging, is that they are more likely to develop chronic health conditions such as heart diseases, cancer, and diabetes – all of which require ongoing medical care.
Novo Nordisk, a Lunar Capital holding, is a Danish pharmaceutical company that specialises in the development and manufacturing of treatments for diabetes, obesity, and other chronic diseases. Novo Nordisk, along with Eli Lilly (another Lunar Capital holding) are two of the leading players treating chronic medical-conditions.
Ozempic, a popular treatment developed by Novo Nordisk, was initially used to treat type-2 diabetes. However, it was discovered that Ozempic influences weight loss as well. The medication produces a digestive hormone called glucagon that ultimately reduces appetite, leading to weight loss in patients. In the United States, Ozempic is currently only FDA-approved drug for use in treating type-2 diabetes. However, some physicians may prescribe Ozempic for off-label use, which allows them to prescribe the medication for other conditions, such as treating obesity. Some studies indicate that approximately 40% of people in the USA are obese, providing a large market for drugs such as Ozempic.
Pharmaceutical companies operate in a highly regulated industry with country-specific requirements that can be challenging to navigate. Developing new treatments is a lengthy and costly process with no guarantees of success, but these companies invest heavily in research and development to remain competitive. However, the industry’s public-facing nature means that any negative outcomes or unintended consequences from treatments could result in significant reputational and financial losses. Nonetheless, if pharmaceutical companies can navigate these challenges successfully, they can be compensated well for it.
Connect with us on social media:
Lunar Capital on Eastwave Radio
Every Tuesday, at 07h45, Sabir chats with Nazia from Eastwave Radio (92.2 fm, live stream on www.eastwave.co.za) on investing and the markets.
Click here to access your account to view statements, obtain tax certificates, add, or make changes to your investments.
Our email address is: [email protected]
Read our full Disclosure statement: https://lunarcapital.co.za/disclosures/
Our Privacy Notice: https://lunarcapital.co.za/privacy-policy/
The Lunar BCI Worldwide Flexible Fund Fact Sheet can be read here.
This roundup is prepared for the clients of Lunar Capital (Pty) Ltd. This roundup does not constitute financial advice and is generated for information purposes only.